Oruka Therapeutics Inc ORKA

$84.52 +1.10 (1.32%)

Valuation

Market cap
5,523,238,000
Revenue TTM
$0
Net income TTM
$-105,430,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
581,400
Avg volume
879,274
Day's range
$83.33 – $86.00
Shares out
66,210,000
Stochastic %K
22%
Beta
-0.37
Analysts
Strong Sell
Price target
$149.31

Price

Company profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phas...

Show more

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 606 7910
Website
https://orukatx.com
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, United States

Latest news

Stocktwits

Merlintrader Sep 27, 5:16 PM
Oruka Therapeutics ($ORKA) Stock Hub: Can Oruka turn lasting skin clearance into a differentiated psoriasis franchise? https://www.merlintrader.com/oruka-therapeutics-orka-stock-hub/
0 replies
JFais Sep 26, 7:28 PM
From weekend discussions: $XBI - Trump at max pain (rising inflation & interest rates) with midterms approaching = Iran deal more likely? -Debate on investing in truly novel companies like $RVMD vs "me-betters" a la $APGE or $ORKA -Rebound trade in $PHAT, profitability in Q3
1 replies
Tintylatta Sep 24, 9:54 PM
$ORKA see everybody in December when the 52 week phase II readout occurs. I doubt there will be any meaningful upward movement until we get closerto that time point.
0 replies
Quantumup Sep 24, 11:38 AM
H.C. Wainwright reiterated $ORKA Buy-$120 $ABBV APGE $UCBJY PTGX - JNJ TAK LLY NVS Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2103086429978996837?s=20
0 replies
Whiskeyunderthebed Sep 23, 4:12 PM
$ORKA this is oversold now- they will pick up shares now.
0 replies
notreload_ai Sep 23, 3:47 PM
$ORKA shares dropped even as Week 28 PASI 100 rose to 71.4% with no extra dosing. A classic biotech sell-the-news reaction after a big run-up. Analysts called the readout in line with base case. https://notreload.xyz/xy/oruka-falls-on-sell-the-news-after-strong-week-28-data/
0 replies
Whiskeyunderthebed Sep 23, 3:39 PM
$ORKA
0 replies
Tintylatta Sep 23, 3:17 PM
$ORKA unfortunately what it looks like is that the market is waiting for that 52 week data in December which I continue to remain positive on and that would prove that this could potentially be a once a year dosed product. Today’s read out confirmed six month, durability only.
0 replies